← Leaderboards
Neal L Benowitz
University Of California San Francisco
$31,329,042
Attributed
$34,228,113
Total exposure
33
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$51,360,589 · 35
By mechanism
R01$22,508,454 · 7
U01$14,966,582 · 6
P30$10,529,436 · 3
T32$1,611,965 · 1
R37$1,575,641 · 1
M01$168,511 · 17
Top collaborators
- Reese T. Jones12 shared
- Judith J. Prochaska8 shared
- Caroline Cremo Renner4 shared
- Matthew Schnellbaecher4 shared
- Hongying Daisy Dai2 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Reese T. Jones$7,250,168
- Sharon M. Hall$13,779,932
- Mark L Rubinstein$3,340,237
Others in their field
Top investigators on “Nicotine”
- Dorothy K Hatsukami · University Of Minnesota Twin Cities$52,725,890
- Stephen T Higgins · University Of Vermont &St Agric College$41,481,617
- Caryn Lerman · University Of Southern California$26,022,644
- Stephen S Hecht · University Of Minnesota$25,906,702
- Marina R. Picciotto · Yale University$25,752,267
- Kenneth Robert Williams · Yale University$24,418,396
Research focus
NicotineClinical ResearchSmokingHuman SubjectDrug MetabolismSmoking CessationSmokerProgramsTobaccoDrug KineticsAddictionTobacco AbuseMetabolismLaboratoriesCotinineBiological MarkersResponseCigaretteTobacco UseResearch PersonnelCostAreaCigarette SmokingExposure To
Grant awards (156)
Health Effects of E-cigarette Use on Brain Functions and Cognitive Development among Adolescents: A US Population-Based Study$367,729
R01 · FY2025 · DA
Clinical Pharmacology of Nicotine Enantiomers$700,343
R01 · FY2024 · DA · contact PI
Health Effects of E-cigarette Use on Brain Functions and Cognitive Development among Adolescents: A US Population-Based Study$393,141
R01 · FY2024 · DA
Clinical Pharmacology of Nicotine Enantiomers$708,762
R01 · FY2023 · DA · contact PI
Cigarette Harm Reduction with Scheduled Electronic Cigarette Use$790,521
U01 · FY2021 · DA · contact PI
Clinical Pharmacology of Electronic Cigarettes$752,196
R01 · FY2021 · DA · contact PI
Clinical Pharmacology of Electronic Cigarettes$752,196
R01 · FY2020 · DA · contact PI
Clinical Pharmacology of Electronic Cigarettes$747,662
R01 · FY2019 · DA · contact PI
Drug Dependence Clinical Research Program$721,926
P30 · FY2019 · DA
Cigarette Harm Reduction with Scheduled Electronic Cigarette Use$788,615
U01 · FY2018 · DA · contact PI
Drug Dependence Clinical Research Program$731,167
P30 · FY2018 · DA
Technology Innovations for Supporting Health in Alaska Native People$697,388
R01 · FY2018 · HL
Drug Dependence Clinical Research Program$737,129
P30 · FY2017 · DA
Clinical Pharmacology of Electronic Cigarettes$710,188
R01 · FY2017 · DA · contact PI
Technology Innovations for Supporting Health in Alaska Native People$705,392
R01 · FY2017 · HL
Drug Dependence Clinical Research Program$736,092
P30 · FY2016 · DA
Technology Innovations for Supporting Health in Alaska Native People$729,321
R01 · FY2016 · HL
Clinical Pharmacology of Electronic Cigarettes$708,750
R01 · FY2016 · DA · contact PI
Clinical Pharmacology of Electronic Cigarettes$127,209
R01 · FY2016 · DA · contact PI
Technology Innovations for Supporting Health in Alaska Native People$781,927
R01 · FY2015 · HL
Drug Dependence Clinical Research Program$752,573
P30 · FY2015 · DA
Clinical Pharmacology of Electronic Cigarettes$686,877
R01 · FY2015 · DA · contact PI
Drug Dependence Clinical Research Program$456,501
P30 · FY2015 · DA
Technology Innovations for Supporting Health in Alaska Native People$777,761
R01 · FY2014 · HL
Drug Dependence Clinical Research Program$595,917
P30 · FY2014 · DA
Laboratory Resource$529,468
P30 · FY2014 · DA · contact PI
Mechanisms of the Nicotine Metabolism Effect on Tobacco Dependence$405,507
R01 · FY2014 · DA · contact PI
Drug Dependence Clinical Research Program$228,252
P30 · FY2014 · DA
Technology Innovations for Supporting Health in Alaska Native People$35,596
R01 · FY2014 · HL
Technology Innovations for Supporting Health in Alaska Native People$28,654
R01 · FY2014 · HL
Technology Innovations for Supporting Health in Alaska Native People$21,915
R01 · FY2014 · HL
University of California, San Francisco (UCSF)$19,955
U01 · FY2014 · DA · contact PI
Drug Dependence Clinical Research Program$581,298
P30 · FY2013 · DA
Laboratory Resource$526,604
P30 · FY2013 · DA · contact PI
Mechanisms of the Nicotine Metabolism Effect on Tobacco Dependence$400,087
R01 · FY2013 · DA · contact PI
University of California, San Francisco (UCSF)$19,747
U01 · FY2013 · DA · contact PI
Pharmacokinetics and Pharmacodynamics of Nicotine$619,380
R01 · FY2012 · DA · contact PI
Drug Dependence Clinical Research Program$608,690
P30 · FY2012 · DA
Laboratory Resource$541,529
P30 · FY2012 · DA · contact PI
Mechanisms of the Nicotine Metabolism Effect on Tobacco Dependence$429,807
R01 · FY2012 · DA · contact PI
University of California, San Francisco (UCSF)$103,198
U01 · FY2012 · DA · contact PI
University of California, San Francisco (UCSF)$21,146
U01 · FY2012 · DA · contact PI
Pharmacokinetics and Pharmacodynamics of Nicotine$636,591
R01 · FY2011 · DA · contact PI
Drug Dependence Clinical Research Program$628,100
P30 · FY2011 · DA
Laboratory Resource$560,580
P30 · FY2011 · DA · contact PI
TOBACCO CONTROL PROGRAM$69,688
P30 · FY2011 · CA · contact PI
University of California, San Francisco (UCSF)$21,853
U01 · FY2011 · DA · contact PI
Pharmacokinetics and Pharmacodynamics of Nicotine$658,878
R01 · FY2010 · DA · contact PI
Drug Dependence Clinical Research Program$657,448
P30 · FY2010 · DA
Laboratory Resource$584,933
P30 · FY2010 · DA · contact PI
TOBACCO CONTROL PROGRAM$70,560
P30 · FY2010 · CA · contact PI
University of California, San Francisco (UCSF)$21,713
U01 · FY2010 · DA · contact PI
Pharmacogenetics of Nicotine Addiction and Treatment$1,724,567
U01 · FY2009 · DA · contact PI
Pharmacokinetics and Pharmacodynamics of Nicotine$666,546
R01 · FY2009 · DA · contact PI
Clinical Core$631,315
U01 · FY2009 · DA · contact PI
Safety of Nicotine Reduction Strategy$535,700
R01 · FY2009 · CA · contact PI
Leadership Core$111,593
U01 · FY2009 · DA · contact PI
Pharmacogenetics of Nicotine Addiction and Treatment$101,469
U01 · FY2009 · DA · contact PI
Clinical Pharmacology, Drug Action & Pharmacogenetics$100,473
T32 · FY2009 · GM · contact PI
TOBACCO CONTROL PROGRAM$71,725
P30 · FY2009 · CA · contact PI
Pharmacogenetics of Nicotine Addiction and Treatment$1,846,187
U01 · FY2008 · DA · contact PI
Pharmacokinetics and Pharmacodynamics of Nicotine$672,482
R01 · FY2008 · DA · contact PI
Clinical Core$592,295
U01 · FY2008 · DA · contact PI
Safety of Nicotine Reduction Strategy$563,228
R01 · FY2008 · CA · contact PI
Clinical Pharmacology, Drug Action & Pharmacogenetics$192,620
T32 · FY2008 · GM · contact PI
Leadership Core$104,695
U01 · FY2008 · DA · contact PI
TOBACCO CONTROL PROGRAM$74,361
P30 · FY2008 · CA · contact PI
Pharmacogenetics of Nicotine Addiction and Treatment$2,015,780
U01 · FY2007 · DA · contact PI
PHARMACOKINETICS AND PHARMACODYNAMICS OF NICOTINE$674,044
R01 · FY2007 · DA · contact PI
Clinical Core$600,805
U01 · FY2007 · DA · contact PI
Safety of Nicotine Reduction Strategy$570,509
R01 · FY2007 · CA · contact PI
Clinical Pharmacology, Drug Action & Pharmacogenetics$190,612
T32 · FY2007 · GM · contact PI
Leadership Core$95,834
U01 · FY2007 · DA · contact PI
TOBACCO CONTROL PROGRAM$64,895
P30 · FY2007 · CA · contact PI
Pharmacogenetics of Nicotine Addiction and Treatment$2,009,380
U01 · FY2006 · DA · contact PI
PHARMACOKINETICS AND PHARMACODYNAMICS OF NICOTINE$592,926
R01 · FY2006 · DA · contact PI
CORE--CLINICAL$539,305
U01 · FY2006 · DA · contact PI
Clinical Pharmacology, Drug Action & Pharmacogenetics$188,512
T32 · FY2006 · GM · contact PI
Safety of Nicotine Reduction Strategy$111,354
R01 · FY2006 · CA · contact PI
Pharmacogenetics of Nicotine Addiction and Treatment$2,000,000
U01 · FY2005 · DA
CORE--CLINICAL$600,822
U01 · FY2005 · DA
PHARMACOKINETICS AND PHARMACODYNAMICS OF NICOTINE$589,509
R01 · FY2005 · DA
Safety of Nicotine Reduction Strategy$487,777
R01 · FY2005 · CA
PROJECT 1 (LEADERSHIP CORE)$205,787
U01 · FY2005 · DA
Clinical Pharmacology, Drug Action &Pharmacogenetics$188,512
T32 · FY2005 · GM
EFFECTS OF NICOTINE ON DRUG METABOLISM$40,616
M01 · FY2005 · RR
CARDIOVASCULAR EFFECTS OF CIGARETTE SMOKING COMPARED TO TRANSDERMAL NICOTINE$23,652
M01 · FY2005 · RR
BIOCHEMICAL ASSESSMENT OF LOW LEVEL NICOTINE EXPOSURE$14,681
M01 · FY2005 · RR
PHARMACOGENETIC STUDY OF NICOTINE METABOLISM$9,135
M01 · FY2005 · RR
EFFECTS OF GRAPEFRUIT JUICE ON ORAL NICOTINE PHARMACOKINETICS$7,503
M01 · FY2005 · RR
MENTHOL CIGARETTES AND NITROSAMINE METABOLISM$6,199
M01 · FY2005 · RR
ETHNIC DIFFERENCES OF NICOTINE IN NON-SMOKERS$2,120
M01 · FY2005 · RR
VASOACTIVE SUBSTANCES IN BP DYSREGULATION$326
M01 · FY2005 · RR
Safety of Nicotine Reduction Strategy$596,380
R01 · FY2004 · CA
PHARMACOKINETICS AND PHARMACODYNAMICS OF NICOTINE$572,339
R01 · FY2004 · DA
CLINICAL, PHARMACOLOGY, DRUG ACTION &PHARMACOKINETICS$134,862
T32 · FY2004 · GM
Effects of nicotine on drug metabolism$20,133
M01 · FY2004 · RR
Biochemical assessment of low level nicotine exposure$17,597
M01 · FY2004 · RR
Ethnic differences of nicotine in non-smokers$10,939
M01 · FY2004 · RR
Menthol cigarettes and nitrosamine metabolism$7,927
M01 · FY2004 · RR
Pharmacogenetic study of nicotine metabolism$2,854
M01 · FY2004 · RR
Vasoactive substances in BP dysregulation$317
M01 · FY2004 · RR
PHARMACOKINETICS AND PHARMACODYNAMICS OF NICOTINE$584,007
R01 · FY2003 · DA
CLINICAL, PHARMACOLOGY, DRUG ACTION &PHARMACOKINETICS$182,909
T32 · FY2003 · GM
SAFETY OF A NICOTINE REDUCTION STRATEGY$585,563
R01 · FY2002 · CA
PHARMACOKINETICS AND PHARMACODYNAMICS OF NICOTINE$539,194
R37 · FY2002 · DA
CLINICAL, PHARMACOLOGY, DRUG ACTION &PHARMACOKINETICS$176,675
T32 · FY2002 · GM
NICOTINE KINETICS IN TWINS$0
M01 · FY2002 · RR
NICOTINE KINETICS IN TWINS$0
M01 · FY2002 · RR
EFFECTS OF MECAMYLAMINE ON NICOTINE DISPOSITION &PHARMACODYNAMICS$0
M01 · FY2002 · RR
EFFECTS OF MECAMYLAMINE ON NICOTINE DISPOSITION &PHARMACODYNAMICS$0
M01 · FY2002 · RR
EFFECTS OF MENSTRUAL CYCLE ON METABOLISM AND EFFECTS OF NICOTINE$0
M01 · FY2002 · RR
EFFECTS OF MENSTRUAL CYCLE ON METABOLISM AND EFFECTS OF NICOTINE$0
M01 · FY2002 · RR
MENTHOLATED CIGARETTES AND NICOTINE METABOLISM$0
M01 · FY2002 · RR
MENTHOLATED CIGARETTES AND NICOTINE METABOLISM$0
M01 · FY2002 · RR
VASOACTIVE SUBSTANCES IN BLOOD PRESSURE DYSREGULATION SYNDROMES$0
M01 · FY2002 · RR
VASOACTIVE SUBSTANCES IN BLOOD PRESSURE DYSREGULATION SYNDROMES$0
M01 · FY2002 · RR
METABOLISM AND CLEARANCE OF NICOTINE IN PREGNANT WOMEN$0
M01 · FY2002 · RR
METABOLISM AND CLEARANCE OF NICOTINE IN PREGNANT WOMEN$0
M01 · FY2002 · RR
STABLE ISOTOPE STUDIES OF NICOTINE AND COTININE METABOLISM$0
M01 · FY2002 · RR
STABLE ISOTOPE STUDIES OF NICOTINE AND COTININE METABOLISM$0
M01 · FY2002 · RR
SAFETY OF A NICOTINE REDUCTION STRATEGY$569,308
R01 · FY2001 · CA
PHARMACOKINETICS AND PHARMACODYNAMICS OF NICOTINE$525,076
R37 · FY2001 · DA
CLINICAL, PHARMACOLOGY, DRUG ACTION &PHARMACOKINETICS$105,393
T32 · FY2001 · GM
VASOACTIVE SUBSTANCES IN BLOOD PRESSURE DYSREGULATION SYNDROMES$0
M01 · FY2001 · RR
METABOLISM AND CLEARANCE OF NICOTINE IN PREGNANT WOMEN$0
M01 · FY2001 · RR
STABLE ISOTOPE STUDIES OF NICOTINE AND COTININE METABOLISM$0
M01 · FY2001 · RR
EFFECTS OF MECAMYLAMINE ON NICOTINE DISPOSITION &PHARMACODYNAMICS$0
M01 · FY2001 · RR
EFFECTS OF MENSTRUAL CYCLE ON METABOLISM AND EFFECTS OF NICOTINE$0
M01 · FY2001 · RR
MENTHOLATED CIGARETTES AND NICOTINE METABOLISM$0
M01 · FY2001 · RR
NICOTINE KINETICS IN TWINS$0
M01 · FY2001 · RR
SAFETY OF A NICOTINE REDUCTION STRATEGY$553,525
R01 · FY2000 · CA
PHARMACOKINETICS AND PHARMACODYNAMICS OF NICOTINE$511,371
R37 · FY2000 · DA
CLINICAL, PHARMACOLOGY, DRUG ACTION &PHARMACOKINETICS$151,397
T32 · FY2000 · GM
EFFECTS OF MENSTRUAL CYCLE ON METABOLISM AND EFFECTS OF NICOTINE$564
M01 · FY2000 · RR
NICOTINE KINETICS IN TWINS$564
M01 · FY2000 · RR
EFFECTS OF MECAMYLAMINE ON NICOTINE DISPOSITION &PHARMACODYNAMICS$564
M01 · FY2000 · RR
STABLE ISOTOPE STUDIES OF NICOTINE AND COTININE METABOLISM$564
M01 · FY2000 · RR
METABOLISM AND CLEARANCE OF NICOTINE IN PREGNANT WOMEN$564
M01 · FY2000 · RR
VASOACTIVE SUBSTANCES IN BLOOD PRESSURE DYSREGULATION SYNDROMES$564
M01 · FY2000 · RR
DISPOSITION KINETICS &EFFECTS OF MENTHOL$564
M01 · FY2000 · RR
MENTHOLATED CIGARETTES AND NICOTINE METABOLISM$564
M01 · FY2000 · RR
STABLE ISOTOPE STUDIES OF NICOTINE AND COTININE METABOLISM$0
M01 · FY2000 · RR
NICOTINE KINETICS IN TWINS$0
M01 · FY2000 · RR
NICOTINE KINETICS IN TWINS$0
M01 · FY2000 · RR
EFFECTS OF MECAMYLAMINE ON NICOTINE DISPOSITION &PHARMACODYNAMICS$0
M01 · FY2000 · RR
EFFECTS OF MECAMYLAMINE ON NICOTINE DISPOSITION &PHARMACODYNAMICS$0
M01 · FY2000 · RR
EFFECTS OF MENSTRUAL CYCLE ON METABOLISM AND EFFECTS OF NICOTINE$0
M01 · FY2000 · RR
EFFECTS OF MENSTRUAL CYCLE ON METABOLISM AND EFFECTS OF NICOTINE$0
M01 · FY2000 · RR
MENTHOLATED CIGARETTES AND NICOTINE METABOLISM$0
M01 · FY2000 · RR
MENTHOLATED CIGARETTES AND NICOTINE METABOLISM$0
M01 · FY2000 · RR
VASOACTIVE SUBSTANCES IN BLOOD PRESSURE DYSREGULATION SYNDROMES$0
M01 · FY2000 · RR
VASOACTIVE SUBSTANCES IN BLOOD PRESSURE DYSREGULATION SYNDROMES$0
M01 · FY2000 · RR
METABOLISM AND CLEARANCE OF NICOTINE IN PREGNANT WOMEN$0
M01 · FY2000 · RR
METABOLISM AND CLEARANCE OF NICOTINE IN PREGNANT WOMEN$0
M01 · FY2000 · RR
STABLE ISOTOPE STUDIES OF NICOTINE AND COTININE METABOLISM$0
M01 · FY2000 · RR